MapLight Therapeutics, Inc. (NASDAQ: MPLT) recently saw significant insider activity as Chief Financial Officer Vishwas Setia disposed of a portion of his holdings in the company. Between May 4 and May 6, 2026, Setia sold a total of 36,371 shares of common stock. The aggregate value of these transactions reached $1,024,719, with share prices being executed at a weighted average ranging from $27.36 to $30.12.
The sale was not an ad hoc decision but was performed under a Rule 10b5-1 trading plan, which had been adopted by the CFO on December 29, 2025. After finalizing these transactions, Setia remains a significant stakeholder, directly owning 356,256 shares of MapLight Therapeutics common stock.
Market Context and Stock Performance
The divestment comes at a time when the company's equity has experienced notable movements. Currently trading at $29.08, MPLT is positioned near its 52-week high of $33.28. Looking at longer-term performance metrics, the stock has realized a 58% gain over the past year and an 86% surge throughout the last six months. However, this upward momentum was tempered by a recent decline of approximately 9% in the past week. Some analyses suggest that the current share price may represent a slight overvaluation for the company.
Clinical Pipeline and Research Progress
Beyond the executive stock activity, MapLight Therapeutics is navigating critical milestones in its clinical research program. The company has reached two major enrollment objectives:
- ZEPHYR Trial: Enrollment is now complete for this Phase 2 study of ML-007C-MA, which focuses on treating schizophrenia.
- IRIS Trial: The final patient visit has been completed for the Phase 2 trial of ML-004, targeting autism spectrum disorder.
Investors are closely monitoring these developments, as the company is scheduled to release topline results from both clinical trials by mid-August 2026.
Analyst Perspectives
Financial institutions have maintained an optimistic outlook on MapLight's potential in the central nervous system and neuropsychiatric sectors. TD Cowen recently initiated coverage with a buy rating, specifically highlighting the prospects of ML-007C-MA to improve outcomes for patients with schizophrenia. Furthermore, Stifel has reiterated its buy rating, maintaining a price target of $28.00. Stifel's analysis notes that the Phase 2 data readout for ML-007C-MA is expected in the third quarter of 2026 and expressed interest in the M1/M4 mechanism regarding its potential advantages in safety, dosing frequency, or tolerability.